Chronic News and Research

RSS

Systagenix introduces world's first rapid point of test in wound care

Innovation doesn't come easy" says Steve Atkinson, Systagenix CEO "and neither do great brands, yet our team have been responsible for many innovations within this field over the last four decades. We are now introducing the world's first rapid point of care test in wound care to help clinicians choose the most appropriate dressings and therapies for their patients and monitor their efficacy over time.

3 Nov 2010

Kaiser Permanente awards 792 grants in third quarter 2010

Kaiser Permanente, one of the country's largest not-for-profit health care organizations, funded 792 grants nationwide, totaling approximately $16 million in the third quarter of 2010. Grants awarded to organizations this quarter included funding basic human services in California in a tight economy, offering dental care to women and children in the Mid-Atlantic States, and providing college scholarships to high school students in the Northwest to pursue careers in health care.

3 Nov 2010

Eliminating copayments for high-value prescription drugs improves employees' adherence to treatment regimens

An initiative by the U. S. technology company Pitney Bowes to make medications of proven value less expensive for their employees succeeded in stabilizing employees' adherence to their treatment regimens, according to a Commonwealth Fund-supported study published in this month's Health Affairs.

3 Nov 2010

Immense potential for digitized personal health records in chronic disease management

Faster and more widely available internet access has improved our lives in many ways but healthcare is lagging behind, according to researchers writing in the International Journal of Medical Engineering and Informatics.

3 Nov 2010

U.S. models of primary care improves quality of life in older patients with multiple chronic conditions

In a review of comprehensive primary care programs for older adults with multiple chronic conditions, authors identified three models that appear to have the greatest potential for improving quality of care and life for these patients, while reducing or not increasing the costs of their health care, according to an article in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Exact Sciences awarded $244,500 federal grant to develop Cologuard sDNA screening test

Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.

3 Nov 2010

DARA awarded $0.5M grant under Patient Protection and Affordable Care Act for advancing KRN5500 and DB959

DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.

3 Nov 2010

Synergenz awarded $94,836 research grant under federal QTDP program

Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010

Neoprobe receives $244,479 grant under QTDP program

Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has been awarded a grant of $244,479 under the qualifying therapeutic discovery project program established under Section 48D of the Internal Revenue Code.

3 Nov 2010

BioCryst receives $1.1 million in grants under QTDP program

BioCryst Pharmaceuticals, Inc. today announced that the Company had been awarded $1.1 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the Company's clinical programs for peramivir, BCX4208 and forodesine, as well as the pre-clinical BCX4161 kallikrein inhibitor and JAK inhibitor programs.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

CVS Caremark supports FDA pathway for approval of biogeneric options

CVS Caremark reiterated the company's support that the U.S. Food and Drug Administration (FDA) implement regulations necessary to approve biogeneric drugs under the Affordable Care Act. The company's Senior Vice President of Specialty Pharmacy Operations, Scott Reid, testified before the FDA today during a public hearing to address the development of an approval pathway for biosimilar and interchangeable biological products held at the agency's headquarters in Silver Spring, Maryland.

3 Nov 2010

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.

3 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

Somaxon awarded $245,000 grant for Silenor under QTDP program

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

3 Nov 2010

Mouse study indicates black raspberries can prevent colorectal cancer

Black raspberries are highly effective in preventing colorectal tumors in two mouse models of the disease, according to a University of Illinois at Chicago study. The findings are published in the November issue of Cancer Prevention Research.

3 Nov 2010

Health IT: Apps; Competitive contracts; Electronic medical records

The Wall Street Journal: "Indian technology companies are eyeing a coming wave of U.S. spending to digitize health care records. But sensitivity over outsourcing and resistance by American hospitals to sending medical information overseas could thwart efforts to win big contracts." Next year, the U.S. government will dispense billions to "health-care providers who adopt electronic medical records." Doctors are also facing "a federal mandate to upgrade software as the U.S. switches to a new system of insurance billing codes."

3 Nov 2010

Talecris announces launch of PROLASTIN-C in Canada

Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.

3 Nov 2010

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Two federal courts have ruled that the Obama administration is using overly strict standards to determine whether older Americans are entitled to Medicare coverage of skilled nursing home care and home health care.

3 Nov 2010

Chronic News and Research

Systagenix introduces world's first rapid point of test in wound care

Kaiser Permanente awards 792 grants in third quarter 2010

Eliminating copayments for high-value prescription drugs improves employees' adherence to treatment regimens

Immense potential for digitized personal health records in chronic disease management

U.S. models of primary care improves quality of life in older patients with multiple chronic conditions

Exact Sciences awarded $244,500 federal grant to develop Cologuard sDNA screening test

DARA awarded $0.5M grant under Patient Protection and Affordable Care Act for advancing KRN5500 and DB959

Synergenz awarded $94,836 research grant under federal QTDP program

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

Neoprobe receives $244,479 grant under QTDP program

BioCryst receives $1.1 million in grants under QTDP program

Immunomedics product candidates, technologies receive recognition from QTDP program

CVS Caremark supports FDA pathway for approval of biogeneric options

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Somaxon awarded $245,000 grant for Silenor under QTDP program

Mouse study indicates black raspberries can prevent colorectal cancer

Health IT: Apps; Competitive contracts; Electronic medical records

Talecris announces launch of PROLASTIN-C in Canada

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News